🔍 Pleased to report our sub-cohort analysis of the INTERACT study evaluating IPC and surveillance practice in Australasian solid-organ transplant recipients has just been published in Transplant-ID! doi.org/10.1111/tid.... #TxID @ncicancer.bsky.social @thetxidjournal.bsky.social

Infection Prevention and Surveillance in the Care of Australasian Solid‐Organ Transplant Recipients

This is the first survey of infection prevention/surveillance practice in the care of the Australasian solid-organ transplant population, demonstrating multiple key areas of heterogeneity and highlig...

doi.org

🔔 NEW in the Medical Journal of Australia Prolonged SARS‐CoV‐2 shedding in a lung transplant recipient: time for flexibility in infection prevention? ✍️ Alyssa Pradhan, David Pham, Alexander Brennan, Jen Kok and Priya Garg OPEN ACCESS https://buff.ly/42yLhDb

Australia’s first multi-site study of infections in cancer & transplant patients, PROSPER, is now published in BMJ Open! It will guide future infection prevention & control for this vulnerable group. Read the full article here: bmjopen.bmj.com/content/15/7...

🔥🔥Just published in #CID world-first clinical trial of IFN-a nasal spray vs placebo reduced #COVID 🦠 incidence 📉 by 40% in cancer pts. Well tolerated, safe, effective… Full link here: academic.oup.com/cid/advance-ar…

Always exciting to learn more about novel cellular therapies for IFIs at Westmead Hospital ID week! (And see all the research across the precinct) @westmeadinst.bsky.social #TxID

Pleased to publish the INTERACT study - describing current infection prevention & surveillance practice in the care of Australasian cancer/transplant patients & areas for future research (& thankful to all who participated) 🌟 @ncicancer.bsky.social #TxID #IDSky www.ajicjournal.org/article/S019...

The INTERACT study: Infection prevention and surveillance practice in the care of the Australasian cancer and transplant population

Australasian cancer and transplant populations are expanding, with increased infection risk related to prolonged survivorship and broader use of novel immunosuppressants. To optimise care, standardise...

ajicjournal.org

Our new @txidfellows.bsky.social paper is out! This one on ASP in #TxID. Practical tips for beginners and early career faculty. @courtharrismd.bsky.social @rebeccakumar.bsky.social @divsharma.bsky.social @mirandapharmdmph.bsky.social @hannah-imlay.bsky.social

Antibiotic Steward 🅱️C🆔🅿️🌟@absteward.bsky.social · 2y ago

🆕️🔥Article @thetxidjournal.bsky.social Not Just an Oxymoron: The Utilitarian's Guide to Antimicrobial Stewardship in Transplant Infectious Diseases Table ✨️2: TID ASP opportunities & initiatives #idsky #medsky #Txid onlinelibrary.wiley.com/doi/full/10....

Delighted to have been part of these important ECiL-10 c diff guidelines specific to our haematology patients. #TxID @ncicancer.bsky.social @ichs-global.bsky.social @theebmt.bsky.social www.sciencedirect.com/science/arti...

.@astct.bsky.social has #ID #HSCT #CAR-T guidelines in TCT Journal transplantid.net "GUIDELINES"▶️ "ASTCT Guidelines"📁 #️⃣ 9️⃣ : Mgmt of HHV-6B after HSCT and CAR-T Bonus: Tests for chromosomal integration! Thanks Aneela Majeed @clevelandclinic.bsky.social! transplantid.net/37V7X3QT

Excited to see what the PROSPER study (point prevalence of infections in cancer & transplant) demonstrates.. @ncicancer.bsky.social 🦠 @bmj.com #TxID #IDSky #EpiSky

We were proud to be well represented at the inaugural The Transplantation Society of Australia and New Zealand Infectious Disease Day on 20 June 2025 — a fantastic event co-badged with ASID Immunocompromised Host Special Interest Group.

Pleased to present our subgroup analysis @TSANZ. Would IPC specific to the SOT cohort be valuable? Which HAIs/OIs should we monitor, and how do we build a national framework for success? @ncicancer.bsky.social #TxID #IDSky

Always a pleasure to hear @aussiedocwolfe.bsky.social speak on advances in organ transplantation & thankful to chair a session on infection surveillance in transplant @TSANZ Transplant Infectious Disease day! Congrats to the committee for putting together an exciting inaugural meeting.

Happy Infectious Diseases Pharmacists Day to my colleagues, mentors, and clinician-researcher heroes #IDPharmacistsDay #SIDPAdvocacy @adphaau.bsky.social @sidpharm.bsky.social @ncicancer.bsky.social

Grateful to have received a travel stipend to spend an exciting few days at the @fredhutch.bsky.social ICH Symposium in Seattle, present & learn from experts in the field- Including @kottonnelson.bsky.social, Jay Fishman & our own @ncicancer.bsky.social @michyong.bsky.social, Monica Slavin & more..!

Herpes Simplex Virus and Drug Resistance - Comprehensive Update on Resistance Mutations and Implications for Clinical Management: A Narrative Review Open Access @cmijournal.bsky.social www.clinicalmicrobiologyandinfection.com/article/S119... #IDSky #TxID

Cryptococcal Meningitis Treatment Beyond HIV: Recognizing the need for Individualized Immune-Based Strategies Hyunah Yoon, Liise-anne Pirofsky, @drboulware.bsky.social In non-HIV-associated CM, ⬇️ing immunosuppression --> ⬆️ inflammation --> 🧠 damage. academic.oup.com/cid/advance-... #TxID #IDSky

New from @loukasmd.bsky.social et al: Authors provide systematic review of pathogens & sources of contamination linked to outbreaks in HSCT units ▶️ 39 studies, various sources including water, construction, contamination #IDSky 📄: doi.org/10.1017/ice....

The most anticipated RCT in ID 🔥SNAP RCT🔥The largest RCT 2 date in SA bactermia N:1341 Cefazolin Vs ASPs ((flu)cloxacillin) for MSSA bacteremia Cefazolin is non-inferior (90d mortality)& less AKI than ASPs A practice-changer RCT that must change the guidelines #ESCMIDGlobal #IDSky

Day 2 of the Australasian Society for Infectious Diseases (ASID) ASM in Canberra, our incredible NCIC team proudly showcased their poster presentations. It was a fantastic opportunity to showcase their hard work and dedication to advancing the ICH space on a national stage!

Great to hear work by my friend, fellow ID physician & PhD candidate @dremmalouise.bsky.social & nursing student Jobe Bonney on tackling TB in remote communities at the ASID ASM - excited to hear how the REACT project progresses! @asidaud.bsky.social

Honoured to speak & present our @ncicancer.bsky.social work on infection prevention in cancer/transplant at the Australasian Society of ID ASM with @nikhil-singh.bsky.social @michyong.bsky.social @benwteh.bsky.social, & amazing to hear & see the incredible work done at other centres nationally 👏🏽

Great 1st day at Australasian Society for Infectious Diseases meeting! @michyong.bsky.social led an insightful CMV symposium @benwteh.bsky.social chaired the "What's New in.." session as part of ICHSIG @priyagargiddoc.bsky.social comprehensive talk on key developments and gaps in the ICHS space

Sad to have had my last ‘in-person’ day as a physician at the @petermaccc.bsky.social, Melbourne! A fantastic place to practice, be inspired in #IDOnc #TxID and surrounded by #womeninSTEM! Will continue my PhD through the @ncicancer.bsky.social though, so many more return visits to come 🙌🏽

Excited to receive some @ucla-id-fellowship.bsky.social merch in the post here in Melbourne to use on my next ward round! UCLA Transplant-ID; thank you again- a fabulous team & such great learnings/ collaborative discussions in the care of the high-risk ICH @jschaenmanmd.bsky.social #TxID #IDsky

Next draft Infection Card for Epipocalypse: Bug Detectives: Measles! Unfortunately this is a thing again. Remember the 3 C's and to keep it in your differential! #IDSky #MedSky #EpiSky any feedback or suggestions?

On #WorldCancerDay, we honor those affected by cancer and highlight the EINSTEIN project, which aims to revolutionize infection detection in immunocompromised cancer patients. EINSTEIN uses AI and medical records to detect infections early. Learn more: cancerandinfections.org/infection-su...

Really interesting paper by my colleagues at @domucla.bsky.social - and fits with my own thoughts about the utility/pitfalls of plasma mcfDNA (including low yield of fungal pickup) as well as giving some ideas for future diagnostic stewardship if incorporated into practice @jschaenmanmd.bsky.social

Practice affirming results from our team @victoriahall.bsky.social @ncicancer.bsky.social - No additional benefit from second influenza vaccine dose/adjuvant vaccines in non-HCT haematology patients. #TxID #IDsky #medsky www.nejm.org/doi/full/10....

Influenza Vaccination Strategies in Patients with Hematologic Cancer | NEJM

In this trial involving patients with hematologic cancers, the immune responses that were elicited were similar for adjuvanted-dose and standard-dose influenza vaccines.

nejm.org